◆ Finance
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Was Moderna Stock’s Cancer Vaccine Run Visible In Advance?
September 22nd, 2026 · by Trefis TeamMRNAYTD+486.4%SPYYTD+14.0%XLVYTD+10.1%Analyze MRNA →Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run’s central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
Image from Pixabay When Did Moderna First Put The Melanoma Test On The Calendar?
The case was already building in June 2024, when Moderna reported positive three-year Phase II data for the therapy in adjuvant melanoma, meaning patients treated after their tumors were removed. In early 2025, in its report on the fourth quarter of 2024, the company said the Phase III trial with Merck, pairing the therapy with KEYTRUDA, was fully enrolled. Asked about timing, its President called a 2026 readout possible and plausible, while noting that the trial was event-driven.
The same report carried a warning. A separate Phase III trial of Moderna’s CMV vaccine had not met its criteria for an early win at an interim look.
Find the leak that's costing you the most money.
Paste a hand history and PokerHack ranks your worst mistakes by $EV lost, then shows the exact GTO fix for each one.
What Was The Rest Of Moderna Telling You?
The business pointed the other way. In 2024, the vast majority of the biotech’s sales came from Spikevax, its COVID vaccine. As of its fiscal Q2 2025 results, trailing-twelve-month revenue was $3.06 billion, down 38.8% year over year. In late July 2025, Moderna said it would cut roughly 10% of its workforce amid declining sales of its COVID-19 vaccines.
Yet management kept paying for the cancer work. In early August 2025, the CFO said savings from finishing large trials would be partly offset by spending on the oncology portfolio. The CEO added that Merck was paying half the cost of intismeran. The melanoma trial, meanwhile, was fully enrolled and accruing cases toward its interim analysis.
A company that cuts staff while still funding its cancer work is telling you where it thinks its value sits. That was the plainest sign Moderna gave before the run.
Could You Have Bet On The Melanoma Result Ahead Of Time?
Only on its timing. The signs told you roughly when the test would come, and that Moderna would fund it through the cuts with Merck sharing the bill. They could not tell you the answer, and the CMV interim was a reminder that results can disappoint. A buyer near $25 in September 2025 owned a shrinking vaccine business and a scheduled test with an unknown result.
Você sabia que era um hero call. Por que não fez?
The answer arrived on August 19, 2026, when the trial met its endpoints for both recurrence-free and distant metastasis-free survival. For the next stock with a trial result due on a known timetable, our screen of option implied volatility shows how much movement options traders are pricing in.
Catching The Surge Matters Less Than Keeping It
Catching a move early is a real edge; keeping the gains it produces takes a different discipline. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.